Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad's appo.

Business Wire • Dec 1, 2025

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

MaxCyte, Inc. ( MXCT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Maher Masoud - President, CEO & Executive Director Douglas Swirsky - Chief Financial Officer Conference Call Participants Matthew Larew - William Blair & Company L.L.C., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Hannah Hefley - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Rohan Walcott - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and thank you for standing by.

Seeking Alpha • Nov 13, 2025

MaxCyte Announces Planned CFO Transition in 2026

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in the first half of 2026.

GlobeNewsWire • Nov 12, 2025

MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance.

GlobeNewsWire • Nov 12, 2025

MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue guidance.

GlobeNewsWire • Nov 5, 2025

MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the third quarter 2025 after the U.S. market close on Wednesday, November 5th, 2025. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

GlobeNewsWire • Oct 8, 2025

MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

MaxCyte's Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio's engineered T cell therapies MaxCyte's Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio's engineered T cell therapies

GlobeNewsWire • Oct 6, 2025

MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a reduction of approximately 34% of the Company's global workforce, inclusive of employees engaged through employer-of-record (EOR) arrangements. Anticipated annualized savings as a result of this action are expected to be approximately $13.6 million.

GlobeNewsWire • Sep 22, 2025

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Douglas J. Swirsky - Chief Financial Officer Maher Masoud - President, CEO & Executive Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Hannah Webb Hefley - Stephens Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.

Seeking Alpha • Aug 7, 2025

MaxCyte (MXCT) Q2 Revenue Drops 18%

MaxCyte (MXCT) Q2 Revenue Drops 18%

The Motley Fool • Aug 7, 2025